Advanced melanoma skin cancers used to carry a dismal prognosis.
Data presented at Barcelona European Cancer Congress ( ESMO) shows the prognosis has improved remarkably in the recent years.
Fifty percent of patients are now alive for at-least five years. It is quite a remarkable achievement for immunotherapy.
1. ESMO press release. One in Two Patients with Metastatic Melanoma Alive after Five Years with Combination Immunotherapy [ESMO 2019 Press Release].
Disclaimer: Please note- This blog is NOT medical advice. This blog is purely for information only. See your own doctor to discuss concerns and options relevant for you.